Brain Diseases and Disorders

31

[60] J. Jankovic and A. S. Kapadia, “Functional decline in parkinson dis-

ease.,” Archives of neurology, vol. 58 10, pp. 1611–5, 2001.

[61] C. Raza, R. Anjum, and N. U. A. Shakeel, “Parkinson’s disease: Mecha-

nisms, translational models and management strategies,” Life Sciences,

vol. 226, p. 77–90, 2019.

[62] T. Endo, N. Yoshikawa, H. Fujimura, et al., “Parkinsonian rigidity de-

pends on the velocity of passive joint movement,” Parkinson’s Disease,

vol. 2015, 2015.

[63] F. Bloch, J. L. Houeto, S. T. du Montcel, et al., “Parkinson’s disease

with camptocormia,” Journal of Neurology, Neurosurgery & Psychiatry,

vol. 77, pp. 1223–1228, 2006.

[64] D. K. Kwon, M. Kwatra, J. Wang, et al., “Levodopa-induced dyskinesia

in parkinson’s disease: Pathogenesis and emerging treatment strategies,”

Cells, vol. 11, 2022.

[65] M. W. I. M. Horstink, E. Tolosa, U. Bonuccelli, et al., “Review of the

therapeutic management of parkinson’s disease. report of a joint task

force of the european federation of neurological societies (efns) and the

movement disorder society‐european section (mds‐es). part ii: late (com-

plicated) parkinson’s disease,” European Journal of Neurology, vol. 13,

2006.

[66] N. Tambasco, M. Romoli, and P. Calabresi, “Levodopa in parkinson’s

disease: Current status and future developments,” Current Neurophar-

macology, vol. 16, pp. 1239–1252, 2017.

[67] D. Nyholm and H. Lennernäs, “Irregular gastrointestinal drug absorp-

tion in parkinson’s disease,” Expert Opinion on Drug Metabolism &

Toxicology, vol. 4, pp. 193–203, 2008.

[68] C. Zhuo, X. Zhu, R.-H. Jiang, et al., “Comparison for efficacy and toler-

ability among ten drugs for treatment of parkinson’s disease: A network

meta-analysis,” Scientific Reports, vol. 7, 2017.

[69] P. Huot, T. H. Johnston, J. B. Koprich, et al., “The pharmacology of

l-dopa-induced dyskinesia in parkinson’s disease,” Pharmacological Re-

views, vol. 65, pp. 171–222, 2013.

[70] G. A. Demaagd and A. Philip, “Parkinson’s disease and its manage-

ment: Part 1: Disease entity, risk factors, pathophysiology, clinical pre-

sentation, and diagnosis,” P & T: a peer-reviewed journal for formulary

management, vol. 40 8, pp. 504–32, 2015.

[71] O. Rascol, M. Fabbri, and W. Poewe, “Amantadine in the treatment of

parkinson’s disease and other movement disorders,” The Lancet Neurol-

ogy, vol. 20, pp. 1048–1056, 2021.